by Plus Therapeutics | Feb 20, 2025 | GBM, LM, PBC, Uncategorized
Plus Therapeutics Appoints Michael Rosol, Ph.D., as Chief Development Officer We are excited to announce the appointment of Michael Rosol, Ph.D., as Chief Development Officer at Plus Therapeutics. In this role, Dr. Rosol will oversee the company’s clinical,...
by Plus Therapeutics | Feb 18, 2025 | GBM, LM, PBC, Uncategorized
Plus Therapeutics Secures $5.7 Million in Funding to Advance Cancer Research #PSTV News: Plus Therapeutics has successfully closed a private placement with $3.7 million in upfront proceeds and received a $2.0 million advance payment from the Cancer Prevention and...
by Plus Therapeutics | Feb 11, 2025 | GBM, LM, PBC, Uncategorized
Celebrating Strength and Resilience: Patient Appreciation Month At Plus Therapeutics, we are honored to celebrate #PatientAppreciationMonth and recognize the incredible strength, resilience, and courage of patients facing cancer. 🧡 Every day, we are inspired by those...
by Plus Therapeutics | Feb 4, 2025 | GBM
New Clinical Trial Site Now Enrolling – OSUCCC-James Joins ReSPECT-GBM! We are excited to announce that The Ohio State University Comprehensive Cancer Center – James (OSUCCC – James) has joined our ReSPECT-GBM Clinical Trial as a new investigation site, with Principal...
by Plus Therapeutics | Feb 4, 2025 | GBM, LM, PBC, Uncategorized
Honoring Progress and Hope on World Cancer Day 🔬 Today is #WorldCancerDay, a day dedicated to raising awareness, advancing research, and supporting those affected by cancer. At Plus Therapeutics, we recognize the unwavering dedication of patients, caregivers, and...
Recent Comments